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ABSTRACT
Sjögren’s syndrome (SS) is a complex autoimmune 
rheumatic disease that specifically targets salivary and 
lachrymal glands. As such, patients typically had ocular 
and oral dryness and salivary gland swelling. Moreover, 
skin, nasal and vaginal dryness are frequently present. In 
addition to dryness, musculoskeletal pain and fatigue are 
the hallmarks of this disease and constitute the classic 
symptom triad presented by the vast majority of patients. 
Up to 30% to 50 % of patients with SS may present 
systemic disease; moreover, there is an increased risk for 
the development of non-Hodgkin’s lymphoma that occurs 
in a minority of patients. The present work was developed 
in the framework of the European Reference Network 
(ERN) dedicated to Rare and Complex Connective Tissue 
and Musculoskeletal Diseases (ReCONNET). In line with 
its goals of aiming to improve early diagnosis, treatment 
and care of rare connective and musculoskeletal diseases, 
ERN-ReCONNET set to review the current state of clinical 
practice guidelines (CPGs) in the rare and complex 
connective tissue diseases of interest of the network. 
Therefore, the present work was aimed at providing a state 
of the art of CPGs for SS.
INTRODUCTION
Sjögren’s syndrome (SS) is a complex auto-
immune rheumatic disease that specifically 
targets salivary and lachrymal glands.1 As 
such, patients typically had ocular and oral 
dryness and salivary gland swelling. More-
over, skin, nasal and vaginal dryness are 
frequently present. In addition to dryness, 
musculoskeletal pain and fatigue are the 
hallmarks of this disease and constitute the 
classic symptom triad presented by the vast 
majority of patients. Up to 30% to 50% of 
patients with SS may present systemic disease 
affecting several organ compartments, such 
as articular, pulmonary, neurological or 
kidney involvement.1 2 There is an increased 
risk for the development of non-Hodgkin’s 
lymphoma that occurs in a minority of 
patients.1 2
The diagnosis of SS is made on the basis 
of medical history, physical examination, 
specific ocular and oral evaluation, blood 
tests and salivary gland assessment (biopsy 
and ultrasound).1 2 Treatment focuses on 
relieving symptoms by using artificial tears 
and saliva, sugar-free candy and secretagogue 
drugs such as pilocarpine or cevimeline.2 3 
General symptoms such as pain and fatigue 
are frequently treated with hydroxychloro-
quine. Specific extraglandular involvement 
may require immunosuppressive drugs.3 
Novel biological drugs are in the pipeline for 
the treatment of the disease.4
As a complex multisystemic disease, special-
ised multidisciplinary care is recommended 
for patients with SS. Also, this highlights 
the need for disease-specific clinical prac-
tice guidelines (CPGs) that set the standards 
for the management of SS in terms of diag-
nosis, monitoring, treatment and prognosis. 
These CPGs are key tools that can be used 
in routine clinical care by physicians that 
directly deal with and manage patients with 
Key messages 
What is already known about this subject?
 ► Good quality CPGs on diagnosis and management of 
SS have been recently published.
What does this study add?
 ► A number of unmet needs for SS were identified by 
patients and clinicians.
How might this impact on clinical practice?
 ► There is a major gap in effective specific therapies 
capable of decisively impacting on the outcomes of 
SS.
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SS (rheumatology, ophthalmology, oral medicine and 
other specialties, depending on organ involvement) 
and general practitioners that encounter undiagnosed 
patients with typical SS complaints. The universal avail-
ability and widespread use of CPGs contributes to improve-
ment and standardisation of care, ultimately benefiting 
patients with SS. Moreover, CPGs are important to define 
the areas with poorer evidence, and more unmet needs 
that should constitute the main focus of future research.
The present work was developed in the framework of 
the European Reference Network (ERN)5 6 dedicated 
to Rare and Complex Connective Tissue and Musculo-
skeletal Diseases (ReCONNET).7 In line with its goals of 
aiming to improve early diagnosis, treatment and care of 
rare connective and musculoskeletal diseases, ERN-Re-
CONNET set to review the current state of CPGs in the 
rare and complex connective tissue diseases (CTDs) of 
interest of the network. A systematic literature review 
(SLR) of current evidence-based medicine (EBM) CPGs 
was conducted for each disease, coordinated by junior 
and senior disease coordinators (DCs), and the results 
were presented and discussed in ERN-ReCONNET 
plenary meetings. The present narrative review reports 
on the SLR performed for CPGs related to diagnosis, 
monitoring and treatment of SS.
METHODS
We carried out a systematic search in Medline (PubMed) 
and Embase based on controlled terms (MeSH and 
Emtree) and keywords of this disease (SS) and publica-
tion type (CPGs). We reviewed all the published articles in 
order to identify existing CPGs on diagnosis, monitoring 
and treatment, according to the8 definition: clinical prac-
tice guidelines are statements that include recommenda-
tions intended to optimise patient care that are informed 
by a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options.8
The DCs of the ERN-ReCONNET for SS have assigned 
the work on CPGs to the 14 healthcare providers (HCPs) 
involved, from seven European countries (France, 
Germany, Italy, The Netherlands, Portugal, Romania and 
Slovenia). Moreover, in order to complement the list of 
guidelines provided by Medline and Embase search, the 
group also performed a hand search on a number of 
national and international websites relevant in the field of 
SS and/or clinical guidance. After a first screening among 
papers included in the final list (systematic search+hand 
search) based on title and abstract, full text evaluation was 
conducted to select EBM guidelines. A general assessment 
of the CPGs was performed based on the Appraisal of 
Guidelines for Research & Evaluation II instrument9 not 
for formal appraisal but only to inform discussion. The 
final goal was to perform a broad assessment of current 
guidelines on SS, with input of all HCPs, that would serve 
as basis to define unmet needs. For this matter, a discussion 
group was set for the evaluation of the existing CPGs and 
identification of unmet needs.
The search strategy employed was as follows «Medline 
(PubMed): (“sjogren's syndrome”[MeSH Terms] OR 
(“sjogren's”[All Fields] AND “syndrome”[All Fields]) 
OR “sjogren's syndrome”’[All Fields]) AND (“Practice 
Guideline”’[Publication Type] OR “Practice Guidelines 
As Topic”’[MeSH Terms] OR Practice Guideline[Publi-
cation Type] OR “Practice Guideline”’[Text Word] OR 
“Practice Guidelines”’[Text Word] OR“Guideline”’[Publi-
cation Type] OR “Guidelines As Topic”’[MeSH Terms] OR 
Guideline[Publication Type] OR “Guideline”’[Text Word] 
OR “Guidelines”’[Text Word] OR “Consensus Develop-
ment Conference”’[Publication Type] OR“Consensus 
Development Conferences As Topic”’[MeSH Terms] OR 
“Consensus”’[MeSH Terms] OR “Consensus”’[Text Word] 
OR “Recommendation”’[Text Word] OR “Recommen-
dations”’[Text Word] OR “Best Practice”’[Text Word] 
OR “Best Practices”’[Text Word]). Embase: (‘sjoegren 
syndrome’/exp OR ‘sjoegren syndrome’ OR ‘sicca 
syndrome’ OR ‘sjoegren disease’ OR ‘sjogren disease’ OR 
‘sjogren syndrome’ OR ‘sjogren`s syndrome’) AND (‘prac-
tice guideline’/exp OR ‘practice guideline’ OR ‘practice 
guidelines’/exp OR ‘practice guidelines’ OR ‘clinical 
practice guideline’/exp OR ‘clinical practice guideline’ 
OR ‘clinical practice guidelines’/exp OR ‘clinical practice 
guidelines’ OR ‘clinical practice guidelines as topic’/exp 
OR ‘clinical practice guidelines as topic’ OR ‘guideline’/
exp OR ‘guideline’ OR ‘guidelines’/exp OR ‘guidelines’ 
OR ‘guidelines as topic’/exp OR ‘guidelines as topic’ OR 
‘consensus development’/exp OR ‘consensus develop-
ment’ OR ‘consensus development conference’/exp OR 
‘consensus development conference’ OR ‘consensus devel-
opment conferences’/exp OR ‘consensus development 
conferences’ OR ‘consensus development conferences as 
topic’/exp OR ‘consensus development conferences as 
topic’ OR ‘consensus’/exp OR ‘consensus’ OR ‘recom-
mendation’ OR ‘recommendations’) AND ([embase)]/
lim NOT ([medline)]/lim»
STATE OF THE ART ON CPGS
The flow diagram adapted from the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses state-
ment for the identification of EBM CPGs on SS is repre-
sented in figure 1.10. Systematic database search identi-
fied 742 records that together with 35 records retrieved 
through manual search led to a total of 777 references 
for screening. Title and abstract screening was then 
conducted by HCP representatives, excluding 696 
records. A total of 81 articles were eligible for full text 
assessment, of which 68 were excluded. Main reasons for 
exclusion included articles not related to SS (ie, wrong 
patients’ population) and article type other than guide-
lines (ie, original research or review manuscripts). A few 
articles were recommendations not supported by SLR, 
which were thus not EBM CPGs, the main focus of the 
present work. Finally, six papers were excluded as dupli-
cates. In the end, seven articles were identified as EBM 
CPGs and included for further analysis.
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The major topics of the included CPGs are summarised 
in table 1. We found high-quality EBM up-to-date guide-
lines on diagnosis (specifically addressing four extrag-
landular domains11) and treatment/management (both 
of glandular and extraglandular manifestations12–14 that 
have all been recently published in the last 3 years by Euro-
pean (European League Against Rheumatism (EULAR) 
SS task force; UK), American (USA) and Latin American 
(Brazil) societies/organisations. All of these presented 
high-quality methodology, were based on a thorough SLR 
and presented in a clear, appropriate way, with adequate, 
comprehensive recommendations relevant for clinical 
practice. Three other guidelines provided important 
information on early diagnosis of SS15 or management of 
dryness,16 17 and were evaluated as being of good overall 
quality, although in some instances based on a less robust 
methodological process. Of note, most of the analysed 
recommendations were often based on expert opinion, 
rather than solid evidence, considering the lack of high-
quality studies that is seen in a number of areas of interest 
in SS.
Common aspects focused by the majority of CPGs 
include: (i) the need to reinforce patient education 
in terms of the disease itself and general measures of 
symptom relief and complications prevention; (ii) the 
importance of collaborative multidisciplinary care in 
diagnosis and follow-up of patients with SS; (iii) the 
central role of specialised assessment of patients with 
SS by physicians with expertise and experience in the 
disease and its various aspects.
Concerning diagnosis, the EULAR SS task force has 
provided recommendations for an adequate descrip-
tion of systemic involvement in primary SS, specifically 
for articular, cutaneous, pulmonary and renal manifes-
tations.11 The main goals were to provide guidance on 
clear-cut definitions, prevalence, clinical characteristics 
and diagnostic approach of each of these organ-spe-
cific extraglandular manifestations. As part of the same 
effort, the authors planned three other manuscripts—
not yet published, although preliminary data have been 
recently presented18—addressing recommendation of 
symptomatic and general treatment as well as on treat-
ment of specific complications (muscular, peripheral 
and central nervous system, haematological) included 
or not included in the EULAR SS Disease Activity Index 
(ESSDAI) and lymphoproliferative disease. The same 
EULAR SS task force has elaborated a consensus set of 
recommendations that aid in the establishment of an 
early diagnosis of primary SS.15 They provide a homoge-
neous diagnostic approach to the patients with suspected 
primary SS based on the clinical presentation pattern, and 
specifically those presenting with systemic involvement.
Two papers arising from the patient organisation 
Sjögren’s Syndrome Foundation (SSF) effort of devel-
oping CPG for SS, approach the management of specific 
ocular16 and oral17 dryness and its complications. Foulks 
et al provide a broad review of the evaluation (symptoms 
and signs/tests of tear function) and treatment (topical/
systemic treatments and other approaches) of SS-associ-
ated dry eye and emit recommendations on these areas, 
Sjögren syndrome
Figure 1 Flow diagram representing the search strategy for evidence-based medicine clinical practice guidelines on Sjögren’s 
syndrome. Adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement by Moher et al.10
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including a treatment algorithm based on severity level 
and response to therapy.16 Zero et al developed EBM 
recommendations for patients with SS who were with 
dry mouth, specifically focusing on caries prevention 
measures.17
Treatment of dryness, fatigue and systemic involvement 
has been addressed in three different sets of high-quality 
recommendations proposed by European (UK),14 North 
American (SSF)12 and South American (Brazil)13 organ-
isations. As part of the SSF initiative mentioned above, 
Carsons et al have systematically reviewed available litera-
ture and proposed treatment recommendations in three 
specific areas: biological therapy for sicca and systemic 
manifestations; management of fatigue and use of conven-
tional synthetic disease-modifying antirheumatic drugs 
(csDMARDs) for inflammatory musculoskeletal pain.12 
Valim et al developed treatment guidelines, sponsored by 
the Brazilian Society of Rheumatology, covering a broad 
range of topics: general and patient education measures, 
including references on exercise, vaccination and vitamin 
D supplementation; symptomatic management of dryness 
(oral, ocular and other); systemic treatment of glandular 
and extraglandular manifestations, including csDMARDs 
and biologics, and treatment according to organ-specific 
involvement.13 The British Society of Rheumatology has 
also recently produced National Institute for Clinical 
Excellence-accredited CPGs for the management of 
adults with primary SS.14 This paper provides compre-
hensive recommendations covering the treatment of 
primary SS in its several dimensions: dryness (ocular, oral 
RMD Open
Table 1 Currently available evidence-based medicine clinical practice guidelines on diagnosis and management of SS
Reference Year Country/organisation Main area of focus Topics covered
Ramos-Casals
et al11
2015 EULAR SS task force Characterisation of 
main organ-specific 
extraglandular 
manifestations
Articular, cutaneous, pulmonary, renal 
involvement:
 ► Definition of each clinical feature
 ► Epidemiological description
 ► Key clinical and diagnostic features of 
each domain.
Brito-Zerón et al15 2015 EULAR SS task force Early diagnosis of 
primary SS
Diagnostic approach to primary SS 
suspicion according to the clinical patterns 
of presentation.
Special focus on organ-specific systemic 
disease presentations.
Consensus set of recommendations 
in order to reach an early diagnosis of 
primary SS.
Foulks et al16 2015 USA/Sjögren’s 
Syndrome Foundation
Management of dry eye 
associated with SS
Evaluation of dry eye disease in SS: 
symptom evaluation and diagnostic 
testing.
Treatment of dry eye disease in SS: 
algorithm based on severity level and 
response to therapy.
Zero et al17 2016 USA/Sjögren’s 
Syndrome Foundation
Management of oral 
complications of SS
Strategies for caries prevention in SS.
Carsons et al12 2016 USA/Sjögren’s 
Syndrome Foundation
Treatment of 
rheumatological 
manifestations of SS
Biological therapy for sicca/systemic 
manifestations.
Treatment and management of fatigue.
csDMARDs for inflammatory 
musculoskeletal pain.
Valim et al13 2015 Brazil/Brazilian Society 
of Rheumatology
Treatment of SS General measures and patient education.
Symptomatic management of dryness.
Systemic treatment of glandular and 
systemic manifestations of SS.
Price et al14 2017 UK/British Society of 
Rheumatology
Management of 
dryness and systemic 
disease in adults with 
primary SS
Management of dryness (ocular, oral, 
systemic).
Management of fatigue and systemic 
disease.
Management of pregnancy.
Risk assessment and monitoring of 
lymphoma.
csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; SS, Sjögren’s 
syndrome.
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and other), salivary gland enlargement, fatigue and use 
of csDMARDs and biologics for systemic disease. More-
over, it addresses briefly the management of pregnancy 
in female patients with SS and lymphoma risk assessment 
and monitoring.
Potential gaps in current existing CPGs
We have identified a few potential gaps in current 
existing guidelines. Several key aspects regarding appli-
cability, implementation (costs/resources) and moni-
toring/update plan of guidelines are generally missing 
in most available recommendations. This is important 
as the application of recommendations in clinical prac-
tice can be limited by local practices and rules (eg, cost, 
availability or approved indication of a given drug), that 
should thus be taken into account. A plan for monitoring 
the application and updating the guidelines should also 
be added, as per the best guidance on guideline elab-
oration methodology. We also consider that a better 
dissemination plan is needed for the current available 
guidelines, and that in some cases, the translation and/
or adoption of these guidelines by other European coun-
tries would be helpful. Moreover, as mentioned above, a 
significant number of recommendations covering several 
areas of SS management and diagnosis are mostly based 
on expert consensus, considering the lack of randomised 
controlled trials (RCTs) and high-quality observational 
studies for SS-related specific questions. Finally, it should 
be noted that 3/7 of the cited CPGs did not include 
patients’ representatives in the working panel, a relevant 
aspect that needs to be taken into account when gener-
ating CPGs.
Other important tools and resources
Despite not constituting the main aim of the present 
SLR, a number of other tools and resources impor-
tant in SS clinical practice were identified and deserve 
mention. International collaborations have success-
fully led to the creation of classification criteria for SS 
that have been widely used in the past two decades, of 
which the most commonly employed are the American 
European Consensus Group 2002 criteria19 and the 
preliminary American College of Rheumatology (ACR) 
2012 criteria.20 Recently, ACR and EULAR have joined 
efforts to develop a single set of data-driven consensus 
classification criteria for primary SS, that may replace 
the former.21 Importantly, these classification criteria are 
primarily oriented for enrolment of patients in clinical 
trials, although being frequently used for guiding diag-
nosis in clinical practice.
In the past decade, the EULAR SS task force committed 
to developing clinical tools that reflect the complex 
nature of SS. From this initiative, important instruments 
have emerged, including the ESSDAI,22 which assesses 
systemic disease activity in its several domains, and the 
EULAR SS Patient Reported Index (ESSPRI),23 which 
translates the most common symptoms reported by 
patients (pain, dryness, fatigue). These indexes have 
been posteriorly complemented with a very useful user 
guide,24 definitions of disease activity states and clinically 
meaningful improvement25 and a simpler, clinical only 
version.26 This comprehensive effort has resulted in the 
fast and widespread incorporation of these tools in clin-
ical practice and research, significantly improving care 
of patients with SS. Together with pre-existent resources 
for evaluating and scoring damage developed by Euro-
pean groups,27 28 they have successfully contributed for 
a global overview of the impact of SS at the individual 
patient level.
Other important resources including guidance and 
recommendations for key areas like salivary gland 
biopsy29 and ultrasound30 and a list of patient organisa-
tions devoted to SS are available at the SS disease info 
toolbox of the ERN-ReCONNET website.31
UNMET NEEDS
Despite considerable advances in recent years regarding 
the development of CPGs specific for SS that decisively 
contribute to improving care of patients with SS, a key 
point common to most recommendations is that they are 
frequently supported by low-to-moderate quality evidence 
and strongly rely on expert opinion. Indeed, there is a 
major need for high-quality studies in several areas of SS 
diagnosis and management in order to further support or 
modify currently available guidelines.32 The most impor-
tant unmet need is the ability or not to recommend, in 
all patients or in a subgroup of patients, a DMARD able 
to change the evolution of the disease. For achieving this 
aim, it is crucial to pursue RCTs that have begun in this 
disease and that recently yielded for the first time a posi-
tive result, in a phase 2 RCT with an anti-CD40 mono-
clonal antibody.33
Historically, despite its considerable prevalence among 
CTDs, SS has been devoted much less research interest, 
time and effort compared with other close conditions, 
such as rheumatoid arthritis, systemic lupus erythema-
tosus or vasculitides.1 As such, clinical approach of SS has 
often mirrored the experience with these other CTDs, 
for which evidence is strongly supported by robust clin-
ical trials and large observational studies. Regardless of 
the obvious similarities with some of these diseases, SS 
is a heterogeneous condition, with different clusters of 
patients defined by typical manifestations and symptoms 
and, therefore, a uniform response is unlikely to be 
seen with most treatments. This underlines the need for 
designing large studies, with several patient subgroups 
and patient’s stratifications, aiming to demonstrate the 
efficacy of csDMARDs, glucocorticoids, biologics and 
novel molecules specifically in SS.
For this matter, active and synergistic involvement of 
patients, clinicians and scientists in the definition of unmet 
needs and areas of future research in SS is crucial. Hope-
fully, these efforts will help to set the path for the elabo-
ration of comprehensive high-quality CPGs, supported by 
a larger body of evidence, which will decisively contribute 
Sjögren syndrome
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to improve and standardise SS patient care. In this 
regard, it is reassuring to learn that patient and scientific 
organisations such as SSF and EULAR have planned to 
develop additional CPGs covering other important ques-
tions, which should become available soon.11 12
Clinicians’ unmet needs
Guidelines proposing a systematic diagnostic approach 
of SS are needed, if possible mostly supported by solid 
data (vs expert consensus). This includes SS in general, 
and organ-specific manifestations not already covered by 
the available CPGs. A specific focus should be given to the 
use/usefulness and standardisation of diagnostic tools, 
including key ones such as minor salivary gland biopsy 
and salivary gland ultrasound and others with potentially 
less current impact like salivary gland scintigraphy and 
sialography.
Regarding treatment, as mentioned, there is an 
important unmet need to be able to recommend, or not, 
a DMARD that definitely changes the evolution of the 
disease in all patients or in a subgroup of patients. Thor-
ough treatment guidance on each specific organ involve-
ment and clear definitions of response/non-response, 
supported by SS studies, are warranted. Importantly, 
EBM recommendations for screening, identification 
and monitoring of patients at high risk of developing 
haematological malignant disorders (most importantly 
non-Hodgkin’s lymphoma) are also missing. Other 
important areas to be addressed by future guidelines 
include: evaluation/approach to cardiovascular risk; 
immunisation strategies of patients with SS; planning and 
management of pregnancy in patients with SS and strat-
egies for assessment of patient burden and SS-related 
quality of life.
A number of unmet needs still exist for the disease and 
patients and significant efforts should be placed in order 
to identify effective symptomatic and systemic therapies 
and biomarkers for stratifying patients, predicting disease 
activity/severity and response to treatment. Validation 
of data arising from small studies should be performed 
in powerful clinical trials, and for that matter, develop-
ment of tools that adequately capture the full picture of 
the disease and are sensitive to change is vital. The same 
applies to evidence imported from other CTDs, that 
should be replicated in patients with SS. Initiatives like 
the ongoing HarmonicSS project will contribute towards 
these aims, through the development of learning tools 
to expand the knowledge of SS for both clinicians and 
patients.34
Regarding patient-reported outcomes (PRO), several 
aspects have to be developed. The ESSPRI score has the 
big advantage of being very simple and thus doable in 
less than 1 min during any patient consultation, but it is 
probably too reductive. Several aspects of fatigue (mental 
or physical), limb pain (musculoskeletal, neurological 
or fibromyalgia-like) and dryness should be developed. 
Likewise, personal patients’ applications for measuring 
PRO more frequently (ie, on a weekly basis) should be 
developed and, indeed, this is one of the tasks of the 
NECESSITY Innovative Medical Initiative project in 
preparation from the European Commission.
Patients’ unmet needs
This paragraph intends to highlight the unmet needs 
of the Sjögren’s Syndrome European community. The 
content of this paragraph has been realised by the ERN 
ReCONNET European Patient Advocacy Group that 
carefully collected the voices and the points of view 
of the whole European community of the disease they 
represent.
Finding a physician that understands Sjögren is still a 
big challenge nowadays, and this is probably the under-
lying cause of the most prevalent reported unmet need: 
delay to diagnosis. Patients are often dismissed because 
doctors can’t relate symptoms, or they are not taken 
seriously. Consequently, lack of understanding from 
family, friends and employers paves the way to a heavy 
emotional burden, not to mention disease progres-
sion-related issues.
Besides early diagnosis, delay to treatment is the 
second most widespread unmet need. It’s not clear 
if doctors don’t know how to treat Sjögren’s or if it’s 
seen exclusively as a dry eyed and dry mouth disease. 
Whether we need combination therapies or new ther-
apeutic targets, the fact is effective and specific treat-
ment lacks, and treatments for Sjögren are largely 
symptomatic. Sjögren’s has been an orphan disease 
in what concerns to specific drugs approval, so estab-
lishing rational targets for drug development is a must. 
Being a highly heterogenous disease, even at molec-
ular level, shows the need for stratification and tailored 
treatment strategy. In this concern, genetics must be 
understood as it seems to play an important role.
Fatigue, pain and cognitive dysfunction, often seen as 
“benign features”, are the cause of greatest patient-re-
ported disability. Understanding how these symptoms 
truly impact patients’ lives and clarifying if depression 
results from disease activity, or is fatigue related, is a big 
challenge that urgently needs to be addressed. Disease 
self-management programme—patient education; 
lifestyle guidelines—along with non-pharmacological 
approaches—exercise; meditation; occupational thera-
pies—are interesting resources that lack to be explored 
and can be key to restore quality of life. There’s life 
beyond the disease and patients deserve to live it at its 
fullest, but they need to be empowered to know how to 
manage it in all circumstances.
Finally, more reliable information is needed to address 
the lack of knowledge from HCPs, public, family, friends 
and employers.
CONCLUSIONS
In the last years, a number of good quality EBM 
recommendations on diagnosis and management of 
SS have been published by national and international 
RMD Open
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organisations. Importantly, patients have been taking 
an active role and joining clinicians to develop CPGs 
and define important areas of future research and 
unmet needs.
However, there is still a need for robust studies 
addressing several key aspects of SS diagnosis and 
treatment to serve as basis for high-quality EBM guide-
lines, which should be implemented across Europe and 
updated regularly. There is a major gap concerning 
specific therapies, predictors and biomarkers for SS that 
may contribute to significantly improve the outcome of 
patients affected by this disease.
Initiatives such as the present one, involving patients 
and experts in multicentre consortiums, contribute 
to raising awareness for complex diseases such as SS 
and to defining key areas of development, ultimately 
leading to improved patient care.
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